Description:
This is a Phase II study in a single center to determine the efficacy of autologous dendritic
cells (DCs) loaded with autogeneic glioma stem-like cells (A2B5+) administered as a
vaccination in adults with glioblastoma multiforme (primary or secondary).
Title
- Brief Title: Study of DC Vaccination Against Glioblastoma
- Official Title: A Triple-blind Randomized Clinical Study of Vaccination With Dendritic Cells Loaded With Glioma Stem-like Cells Associated Antigens Against Brain Glioblastoma Multiform
Clinical Trial IDs
- ORG STUDY ID:
DC81001115
- NCT ID:
NCT01567202
Conditions
- Glioma
- Glioblastoma Multiforme
- Neoplasms
Interventions
Drug | Synonyms | Arms |
---|
Chemotherapy | | Arm DC |
DC vaccination | | Arm DC |
blank placebo | | Arm Placebo |
Purpose
This is a Phase II study in a single center to determine the efficacy of autologous dendritic
cells (DCs) loaded with autogeneic glioma stem-like cells (A2B5+) administered as a
vaccination in adults with glioblastoma multiforme (primary or secondary).
Detailed Description
Despite the advances in diagnosis and treatment (surgery +radiation +chemotherapy), median
survival for patients with newly diagnosed brain glioblastoma multiform (GBM) is about one
year, for recurrent GBM is about 4 months. Recently, immunotherapy has emerged as a novel
treatment strategy for glioma with improving patient survival. Usually, processed tumor
antigens from the patient's own tumor or a peptide vaccine is capable of producing an
anti-glioma response. Our previous experiment revealed that the CD133+ tumor stem-like cells
associated antigens could elicit highly intensive immune response against human malignant
glioma , and in phase I study, we have confirmed that DC vaccine loaded with glioma stem-like
cells associated antigens against malignant glioma in recurrent patients was of safety .
Autologous DCs will be obtained from peripheral blood mononuclear cells (PBMCs) from each
patient. Stem-like cells associated antigens (SAA) will be prepared with glioma stem-like
cells that are harvested from patients with GBM and primary cultured and sorted
flowcytometrically and then irradiated. Approximately 4 weeks will be required for vaccine
production and the first vaccine administration. Each patient will receive an injection of
DCs at his/her assigned dose once every week during the first 6 week. The dose of DCs is
defined as 8~10×10^6.
Clinical trials that utilize DCs for immunotherapy have demonstrated significant survival
benefit for patients who exhibit robust immune responses against tumor cells. Unfortunately,
at the present time the majority of clinical trials were in phase I that illustrated the
safety. The efficacy of DCs against glioblastoma is still lack of sufficient randomized phase
II study. According to our previous phase I study, here we designed this clinical trial in a
triple-blind randomized manner to validate the efficacy of DCs vaccination.
Recently,an exploratory randomized phase II clinical trial have been completed (Cancer
immunology &immunotheapy ,2018,1677,1677-1688 ; PubMed ID: 30159779), 43 GBM patients were
randomized after surgery at a 1:1 ratio to receive either DCV (n = 22) or normal saline
placebo (n = 21). Overall survival (OS) and progression-free survival (PFS) were analysed.
Participants were stratified into different molecular subgroups based on the mutation (MT)
status of isocitrate dehydrogenase (IDH1/2) and telomerase reverse transcriptase (TERT).
Plasma cytokine levels, tumor-infiltrating lymphocyte numbers and immune co-inhibitory
molecules PD-L1 and B7-H4 were also assessed. Multivariate Cox regression analysis revealed
that DCV treatment significantly prolonged OS (p = 0.02) after adjusting for IDH1 and TERT
promoter MT and B7-H4 expression, primary vs recurrent GBM. Among IDH1wild type (WT) TERTMT
patients, DCV treatment significantly prolonged OS (p < 0.01) and PFS (p = 0.03) and
increased plasma levels of cytokines CCL22 and IFN-γ compared with placebo. Patients with low
B7-H4 expression showed significantly prolonged OS (p = 0.02) after DCV treatment.
In the present study, IDH1WTTERTMT subgroups of GBM patients more responsive to GSC DCV-based
specific active-immunotherapy. However,It is noted that IDH1WTTERTMTGBM patients was analysed
in a cohort samples which are not randomlized and the present study population is too small
to evaluate conclusively demographic criteria for entry and patient recruitment. the results
of the present study should be confirmed in a random cohort of IDH1WTTERTMT GBM patients.
Accordingly , we made some modifications to the original plan, and are currently recruiting
new participants.
Trial Arms
Name | Type | Description | Interventions |
---|
Arm DC | Experimental | In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy. | - Chemotherapy
- DC vaccination
|
Arm Placebo | Placebo Comparator | In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy. | - Chemotherapy
- blank placebo
|
Eligibility Criteria
Inclusion Criteria:
1. Patients with histologically confirmed brain glioblastoma multiforme and molecular
subgroups of IDH1 wildtype TERT mutation。
2. Patients with maximum safe resection of the tumor (≥95%) confirmed with contrast MR
within 72 hours after surgery.
3. Age from 18 through 70 years.
4. Karnofsky performance score of ≥ 60%.
5. Adequate organ function within 14 days of study registration including the following:
Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count, (ANC) ≥
1.0×10^9/L, platelets ≥100×10^9/L; hemoglobin ≥ 9 g/dL. Hepatic: bilirubin ≤1.3 mg/dL
or 0-22 mmol/L, aspartate transaminase (AST) and alanine transaminase (ALT) < 3×upper
limit of normal (ULN). Renal: Normal serum Creatinine for age (below) or creatinine
clearance >60 ml/min/1.73 m^2. Electrocardiogram: normal.
6. Written informed consent must be obtained from all patients, with the understanding
that consent may be withdrawn by the subject at any time without prejudice to future
medical care.
Exclusion Criteria:
1. Pregnant or breast-feeding patients. Pregnancy testing will be performed on all
menstruating females within 14 days of study enrollment.
2. Patients with uncontrolled intercurrent illness including, but not limited to ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
or psychiatric illness/social situations that would limit compliance with study
requirements.
3. Patients with history of immune system abnormalities such as hyperimmunity (e.g.,
autoimmune diseases) and hypoimmunity (e.g., myelodysplastic disorders, marrow
failures, AIDS, ongoing pregnancy, transplant immuno-suppression), or medication of
cortisol.
4. Patients with any conditions that could potentially alter immune function (e.g., AIDS,
multiple sclerosis, diabetes, renal failure).
5. Patients currently received any other investigational agents.
Maximum Eligible Age: | 70 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Objective response rate (ORR) of the treatment using DC Vaccination for Glioblastoma with molecular markers for immunotherapy. |
Time Frame: | Every 4 weeks from baseline to 6 months. |
Safety Issue: | |
Description: | The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline.Molecular markers are based on the mutation (MT) status of isocitrate dehydrogenase (IDH1/2) and telomerase reverse transcriptase (TERT). |
Secondary Outcome Measures
Measure: | Progression free survival |
Time Frame: | Every 4 weeks from baseline to 6 months. |
Safety Issue: | |
Description: | Progression free survival is defined as the time from the day in which the patient is enrolled to the date on which tumor progresses or the date on which the patient dies for any cause. |
Measure: | Overall survival |
Time Frame: | within 2 years after the surgery |
Safety Issue: | |
Description: | Overall survival is defined as the time from the day in which the patient is enrolled to the date on which the patient dies for any cause. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Huashan Hospital |
Trial Keywords
- Brain tumor
- Glioma
- Glioblastoma
- Tumor stem cells
- Immunotherapy
- Vaccine
Last Updated
September 9, 2020